Table 2.

Comparison of differentially expressed miRNAs in RA and AS patients before and after three months of the anti-TNF treatment. Statistical characteristics of depicted miRNAs. FC: fold change.

RA samples before vs. after therapy			AS samples before vs. after therapy			RA vs. AS patients before anti-TNF treatment			RA vs. AS patients after anti-TNF treatment
miRNA	p	FC	miRNA	p	FC	miRNA	p	FC	miRNA	p	FC
hsa-miR-19b-3p	0.047	-1.35	hsa-let-7c-5p	0.042	5.21	hsa-miR-125a-5p	0.028	4.31	hsa-let-7e-5p	0.005	6.13
hsa-miR-548n	0.023	-1.66	hsa-let-7f-5p	0.044	10.61	hsa-miR-130b-3p	0.031	4.91	hsa-let-7i-5p	0.004	-1.77
hsa-miR-520 h	0.038	-4.77	hsa-miR-125a-5p	0.023	2.23	hsa-miR-151a-5p	0.012	11.58	hsa-miR-125a-5p	0.020	6.00
hsa-miR-498	0.042	-3.28	hsa-miR-130a-3p	0.010	-1.65	hsa-miR-301a-3p	0.029	4.61	hsa-miR-145-5p	0.012	12.76
			hsa-miR-146a-5p	0.022	-1.67	hsa-miR-324-5p	0.031	5.45	hsa-miR-151a-3p	0.027	3.42
			hsa-miR-18a-5p	0.040	5.05	hsa-miR-376c-3p	0.018	-1.08	hsa-miR-151a-5p	0.027	2.96
			hsa-miR-21-5p	0.045	-1.49	hsa-miR-378 h	0.048	-2.47	hsa-miR-1915-3p	0.033	-2.62
			hsa-miR-22-3p	0.022	-2.22	hsa-miR-411-5p	0.037	-1.77	hsa-miR-221-3p	0.021	1.62
			hsa-miR-23a-3p	0.048	-1.74	hsa-miR-548a-5p	0.008	-3.50	hsa-miR-28-3p	0.044	3.04
			hsa-miR-30a-5p	0.005	-2.82	hsa-miR-548n	0.001	-2.11	hsa-miR-30a-5p	0.050	-2.27
			hsa-miR-362-3p	0.002	-1.86	hsa-miR-548q	0.013	-1.95	hsa-miR-3158-3p	0.033	-2.62
			hsa-miR-374b-5p	0.040	1.48	hsa-miR-579-3p	0.029	-1.60	hsa-miR-324-5p	0.019	4.56
			hsa-miR-548a-5p	0.028	-1.72				hsa-miR-379-5p	0.039	-2.84
			hsa-miR-98-5p	0.023	10.99				hsa-miR-496	0.030	-2.83
									hsa-miR-503-5p	0.012	2.90
									hsa-miR-612	0.024	-3.08
									hsa-miR-649	0.033	-2.62
									hsa-miR-98-5p	0.006	7.32